

Stephen Opat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2542264/publications.pdf>

Version: 2024-02-01

119
papers

6,492
citations

186265
28
h-index

69250
77
g-index

119
all docs

119
docs citations

119
times ranked

6126
citing authors

#	ARTICLE	IF	CITATIONS
1	Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. <i>Blood Advances</i> , 2022, 6, 533-543.	5.2	77
2	Targeted Therapy in Leukaemia, Lymphoma and Myeloma. <i>Journal of Personalized Medicine</i> , 2022, 12, 74.	2.5	1
3	Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA. <i>Blood Advances</i> , 2022, 6, 1651-1660.	5.2	14
4	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. <i>Blood</i> , 2022, 139, 3278-3289.	1.4	83
5	Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 3472-3479.	5.2	12
6	Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II ALL003 study. <i>British Journal of Haematology</i> , 2022, 196, 1209-1218.	2.5	24
7	Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. <i>Leukemia</i> , 2022, 36, 1654-1665.	7.2	9
8	Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia. <i>Cancers</i> , 2022, 14, 2710.	3.7	4
9	Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2022, 198, 790-793.	2.5	4
10	Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience. <i>Internal Medicine Journal</i> , 2021, 51, 1825-1834.	0.8	0
11	Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 112-117.	1.3	5
12	Impact of coronavirus disease 2019 (COVID-19) pandemic isolation measures on the rate of non-COVID-19 infections in hematology patients. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 233-235.	1.8	1
13	An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia. <i>Future Oncology</i> , 2021, 17, 371-387.	2.4	3
14	<sc>WhiMSICAL</sc>: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes. <i>American Journal of Hematology</i> , 2021, 96, E218-E222.	4.1	12
15	Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , 2021, 5, 2577-2585.	5.2	60
16	A Description of the Type, Frequency and Severity of Infections Among Sixteen Patients Treated for T-Cell Lymphoma. <i>Journal of Hematology (Brossard, Quebec)</i> , 2021, 10, 123-129.	1.0	1
17	Safety of rapid injection of undiluted ferric carboxymaltose to patients with iron deficiency anaemia: a <sc>Phase II</sc> single-arm study. <i>Internal Medicine Journal</i> , 2021, 51, 1304-1311.	0.8	1
18	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6323-6332.	7.0	42

#	ARTICLE	IF	CITATIONS
19	Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib. Expert Review of Clinical Pharmacology, 2021, 14, 1329-1344.	3.1	27
20	Salvage radiotherapy associates with durable response for a subset of patients with limited stage refractory DLBCL. Blood Advances, 2021, 5, 5112-5115.	5.2	1
21	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. Journal of Clinical Oncology, 2021, 39, 3853-3865.	1.6	115
22	Real-World Outcomes of Patients with Primary CNS Lymphoma (PCNSL): A Report from the Australasian Lymphoma Alliance (ALA). Blood, 2021, 138, 2532-2532.	1.4	0
23	SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood, 2021, 138, 396-396.	1.4	22
24	A Window Study of Acalabrutinib Plus Rituximab Followed By R-Dhaox (rituximab, dexamethasone,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 (MCL): The Australasian Leukaemia & Lymphoma Group (ALLG) NHL33 Wamm Trial. Blood, 2021, 138, 4516-4516.	1.4	0
25	Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib. Blood, 2021, 138, 1419-1419.	1.4	7
26	Real World Data on the Outcomes of Richter's Transformation of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the Australian Population: An Australasian Lymphoma Alliance Study. Blood, 2021, 138, 1455-1455.	1.4	0
27	First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study. Blood, 2021, 138, 68-68.	1.4	10
28	A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology, 2020, 52, 167-178.	0.6	23
29	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncology, The, 2020, 21, 1433-1442.	10.7	306
30	Caution in Expanding the Use of Abbreviated R-CHOP to Poor-Risk Limited-Stage DLBCL. Journal of Clinical Oncology, 2020, 38, 4221-4222.	1.6	2
31	Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood, 2020, 136, 2027-2037.	1.4	78
32	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood, 2020, 136, 2038-2050.	1.4	281
33	Venous thromboembolism in primary central nervous system lymphoma during frontline chemoimmunotherapy. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 997-1003.	2.3	8
34	Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations. Journal of Physical Education and Sports Management, 2020, 6, a004994.	1.2	7
35	Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2020, 21, 1188-1200.	10.7	208
36	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Advances, 2020, 4, 6009-6018.	5.2	57

#	ARTICLE	IF	CITATIONS
37	ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology, 2020, 38, 8007-8007.	1.6	13
38	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood, 2019, 134, 851-859.	1.4	259
39	Cytarabine-based induction immunochemotherapy in the front-line treatment of older patients with mantle cell lymphoma. Scientific Reports, 2019, 9, 13544.	3.3	8
40	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. New England Journal of Medicine, 2019, 380, 2225-2236.	27.0	599
41	A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. Hematological Oncology, 2019, 37, 253-260.	1.7	5
42	Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. Internal Medicine Journal, 2019, 49, 1070-1080.	0.8	8
43	Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS. HemaSphere, 2019, 3, e187.	2.7	14
44	Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma. Internal Medicine Journal, 2019, 49, 422-433.	0.8	5
45	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, The, 2019, 393, 229-240.	13.7	517
46	Bleeding and thrombotic events occur early in children on durable ventricular assist devices. Thrombosis Research, 2019, 173, 65-70.	1.7	13
47	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. Blood, 2019, 134, 35-35.	1.4	40
48	Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma. Blood, 2019, 134, 5256-5256.	1.4	3
49	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial. Blood, 2019, 134, 499-499.	1.4	23
50	Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial. Blood, 2019, 134, 500-500.	1.4	18
51	An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies. Blood, 2019, 134, 1594-1594.	1.4	7
52	Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma. Blood, 2019, 134, 123-123.	1.4	33
53	The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative. Blood, 2019, 134, 3986-3986.	1.4	2
54	Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL. Blood, 2019, 134, 1600-1600.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Adaptive reprogramming of NK cells in X-linked lymphoproliferative syndrome. <i>Blood</i> , 2018, 131, 699-702.	1.4	5
56	A national pathology review committee for the lymphoma and related diseases registry. <i>Pathology</i> , 2018, 50, S107.	0.6	0
57	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 1530-1542.	10.7	91
58	Anti-CD20 monoclonal antibodies: reviewing a revolution. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2820-2841.	3.3	68
59	Concurrent <i>Mycobacterium tuberculosis</i> infection and nodal marginal zone lymphoma. <i>Pathology</i> , 2018, 50, 464-466.	0.6	0
60	Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018, 132, 4196-4196.	1.4	16
61	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , 2018, 132, 4097-4097.	1.4	5
62	Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 1592-1592.	1.4	6
63	Venetoclax and obinutuzumab in chronic lymphocytic leukemia. <i>Blood</i> , 2017, 129, 2702-2705.	1.4	108
64	Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 1331-1344.	27.0	575
65	Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S380-S381.	0.4	3
66	High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 991-994.	2.5	9
67	Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. <i>Blood Advances</i> , 2016, 1, 31-35.	5.2	57
68	Guidelines for timely initiation of chemotherapy: a proposed framework for access to medical oncology and haematology cancer clinics and chemotherapy services. <i>Internal Medicine Journal</i> , 2016, 46, 964-969.	0.8	8
69	Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. <i>Annals of Hematology</i> , 2016, 95, 667-668.	1.8	18
70	High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenström Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study. <i>Blood</i> , 2016, 128, 1216-1216.	1.4	9
71	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1874-1874.	1.4	2
72	Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). <i>Blood</i> , 2016, 128, 2054-2054.	1.4	8

#	ARTICLE	IF	CITATIONS
73	Improved Survival of Older Patients with Mantle Cell Lymphoma (MCL) with Front-Line Cytarabine-Based Immunochemotherapy. <i>Blood</i> , 2016, 128, 2965-2965.	1.4	2
74	Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study. <i>Blood</i> , 2016, 128, 6-6.	1.4	40
75	Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016, 128, 642-642.	1.4	23
76	Disseminated Enteroviral Infection Associated with Obinutuzumab. <i>Emerging Infectious Diseases</i> , 2015, 21, 1661-1663.	4.3	21
77	The oral iron chelator deferasirox inhibits $\text{NF-}\kappa\text{B}$ mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia. <i>British Journal of Haematology</i> , 2015, 168, 576-582.	2.5	29
78	Bortezomib Yields High Response Rates in Antibody-Mediated Autoimmune Hematological Diseases Refractory to Conventional Immunosuppression. <i>Blood</i> , 2015, 126, 3457-3457.	1.4	3
79	Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions. <i>Blood</i> , 2015, 126, 496-496.	1.4	17
80	The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial. <i>Blood</i> , 2015, 126, 832-832.	1.4	90
81	A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. <i>British Journal of Cancer</i> , 2014, 111, 1072-1079.	6.4	113
82	Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. <i>New England Journal of Medicine</i> , 2014, 370, 1101-1110.	27.0	1,284
83	Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. <i>Neuro-Oncology</i> , 2013, 15, 1068-1073.	1.2	54
84	Factor XIII Assays. <i>Methods in Molecular Biology</i> , 2013, 992, 171-180.	0.9	2
85	ADAMTS13 Antibody Depletion by Bortezomib in Thrombotic Thrombocytopenic Purpura. <i>New England Journal of Medicine</i> , 2013, 368, 90-92.	27.0	110
86	High-dose cytarabine (24g/m^2) in combination with idarubicin (HiDAC) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia. <i>Internal Medicine Journal</i> , 2013, 43, 294-297.	0.8	10
87	Incorporating High-Dose IV Methotrexate Into Initial Therapy Results In Lower Rates Of Central Nervous System (CNS) Relapse In Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2013, 122, 4353-4353.	1.4	4
88	Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial. <i>Blood</i> , 2013, 122, 6-6.	1.4	21
89	SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study. <i>Blood</i> , 2013, 122, 86-86.	1.4	8
90	Obinutuzumab (GA101) plus chlorambucil (Clb) or rituximab (R) plus Clb versus Clb alone in patients with chronic lymphocytic leukemia (CLL) and preexisting medical conditions (comorbidities): Final stage 1 results of the CLL11 (BO21004) phase III trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 7004-7004.	1.6	20

#	ARTICLE	IF	CITATIONS
91	Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. <i>Blood</i> , 2012, 119, 1963-1971.	1.4	313
92	A case of ITP with cauda equina syndrome. <i>Annals of Hematology</i> , 2011, 90, 729-730.	1.8	0
93	Failure of eculizumab to correct paroxysmal cold hemoglobinuria. <i>Annals of Hematology</i> , 2011, 90, 989-990.	1.8	27
94	Refractory <i>Bartonella quintana</i> bacillary angiomatosis following chemotherapy for chronic lymphocytic leukaemia. <i>Journal of Medical Microbiology</i> , 2011, 60, 142-146.	1.8	14
95	Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML. <i>Blood</i> , 2011, 118, 2599-2599.	1.4	7
96	Haemopoietic Improvement Following Iron Chelation for Transfusional Haemosiderosis in Patients with Haematopoietic Neoplasia and Aplastic Anaemia: An Observational Study. <i>Blood</i> , 2011, 118, 5050-5050.	1.4	4
97	Allo-SCT for hematological malignancies in the setting of HIV. <i>Bone Marrow Transplantation</i> , 2010, 45, 584-586.	2.4	14
98	Molecular Analysis of the SEC23B Gene In Patients Affected by Congenital Dyserythropoietic Anemia Type II (CDaII). <i>Blood</i> , 2010, 116, 4227-4227.	1.4	1
99	Whole Brain Radiotherapy and Ara-C In Consolidation Post High-Dose Methotrexate Is Important In Establishing Durable Disease Control In the Treatment of Primary CNS Lymphoma: A Single Centre Observational Study. <i>Blood</i> , 2010, 116, 1776-1776.	1.4	4
100	Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2009, 50, 1964-1968.	1.3	4
101	Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 714-722.	7.0	27
102	Burkitt lymphoma in the setting of common variable immunodeficiency. <i>Annals of Hematology</i> , 2009, 88, 819-820.	1.8	5
103	Bone marrow engraftment in pulmonary vessels. <i>British Journal of Haematology</i> , 2009, 146, 2-2.	2.5	0
104	Aplastic anaemia: autoimmune sequel of thymoma. <i>British Journal of Haematology</i> , 2009, 147, 591-591.	2.5	8
105	The thrombotic thrombocytopenic purpura registry: a new national resource to inform patient care and medical research. <i>Internal Medicine Journal</i> , 2009, 39, 72-73.	0.8	0
106	The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.. <i>Blood</i> , 2009, 114, 2923-2923.	1.4	1
107	Number of Lymphoma-Associated-Macrophages (LAM) Is An Independent Predictor of Survival in Patients with Mantle Cell Lymphoma (MCL).. <i>Blood</i> , 2009, 114, 3944-3944.	1.4	2
108	A drop of vitriol: microspherocytosis following sulphuric acid exposure. <i>British Journal of Haematology</i> , 2008, 140, 596-596.	2.5	3

#	ARTICLE	IF	CITATIONS
109	Oxidative haemolysis due to poppers. <i>British Journal of Haematology</i> , 2008, 142, 328-328.	2.5	1
110	Antiplatelet therapy: present status and future prospects. <i>Expert Opinion on Drug Discovery</i> , 2007, 2, 1035-1040.	5.0	1
111	Allogeneic Peripheral Blood Stem Cell Transplantation for Hematological Malignancies in Patients with HIV.. <i>Blood</i> , 2007, 110, 4941-4941.	1.4	2
112	The Feasibility and Safety of Anticoagulation during Chemotherapy Associated Thrombocytopenia for Thrombotic Complications of Malignancy.. <i>Blood</i> , 2007, 110, 1872-1872.	1.4	0
113	The Utility of Radionuclide Ventriculography (RNV) Prior to Anthracycline Chemotherapy in Patients with Acute Myeloid Leukemia: A Retrospective, Single Institution Study.. <i>Blood</i> , 2007, 110, 4369-4369.	1.4	0
114	An unusual case of indigestion: persistence of phagocytosed Auer rods in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2006, 133, 112-112.	2.5	2
115	The Clinical Utility of the 1-Deamino-8-D-Arginine Vasopressin (DDAVP) Trial in the Management of Patients with Von Willebrand Disease: A Retrospective Study.. <i>Blood</i> , 2006, 108, 1033-1033.	1.4	0
116	A Novel Fusion of RARA to the PRKAR1A Gene, Encoding the Regulatory Subunit Type-I β of Cyclic AMP Dependent Protein Kinase A, in a Variant Acute Promyelocytic Leukaemia.. <i>Blood</i> , 2006, 108, 2343-2343.	1.4	0
117	Failure of rituximab monotherapy in lymphomatoid granulomatosis. <i>European Journal of Haematology</i> , 2005, 75, 172-173.	2.2	22
118	The Recognition of HLA-B27 by Human CD4+ T Lymphocytes. <i>Journal of Immunology</i> , 2001, 167, 2619-2624.	0.8	106
119	Disseminated echovirus infection after allogeneic bone marrow transplantation. <i>Pathology</i> , 1997, 29, 424-425.	0.6	10